$2.09
15.47% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US00461U1051
Symbol
ACRS
Sector
Industry

Aclaris Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Neutral
GlobeNewsWire
about 2 months ago
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00...
Neutral
GlobeNewsWire
4 months ago
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of...
Positive
MarketBeat
4 months ago
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.
Neutral
GlobeNewsWire
4 months ago
Dublin, June 25, 2024 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering. The 7 major rheumatoid arthritis markets reached a value of US$ 27.5 billion in 2023. Looking forward, the 7MM are projected to reach US$ 33.8 billion by 2034, exhibiting a...
Neutral
GlobeNewsWire
5 months ago
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday,...
Neutral
Business Wire
6 months ago
RALEIGH, N.C.--(BUSINESS WIRE)--American Clinical Research Services Announces Strategic Acquisition of Elixia.
Neutral
Seeking Alpha
6 months ago
Aclaris Therapeutics, Inc. (NASDAQ:ACRS ) Q1 2024 Results Conference Call May 7, 2024 5:00 PM ET Company Participants Kevin Balthaser - Chief Financial Officer Neal Walker - Interim Chief Executive Officer Joe Monahan - Chief Scientific Officer Wally Smith - Scientific & Business Development Consultant Conference Call Participants Roger Song - Jefferies Thomas Smith - Leerink Partners Corinne J...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today